AR119864A1 - PCSK9 ANTAGONIST COMPOUNDS - Google Patents

PCSK9 ANTAGONIST COMPOUNDS

Info

Publication number
AR119864A1
AR119864A1 ARP200102432A ARP200102432A AR119864A1 AR 119864 A1 AR119864 A1 AR 119864A1 AR P200102432 A ARP200102432 A AR P200102432A AR P200102432 A ARP200102432 A AR P200102432A AR 119864 A1 AR119864 A1 AR 119864A1
Authority
AR
Argentina
Prior art keywords
compounds
formula
pcsk9
antagonist compounds
pcsk9 antagonist
Prior art date
Application number
ARP200102432A
Other languages
Spanish (es)
Inventor
Hubert B Josien
Abbas M Walji
Harold B Wood
Fa Ding
- Liu Jian Xiang
Thomas Joseph Tucker
Michael Man Lo
- Guo Liangqin Chu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR119864A1 publication Critical patent/AR119864A1/en

Links

Landscapes

  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan los compuestos de fórmula (1), o una sal farmacéuticamente aceptable de los mismos, donde A, X, R¹, y R² son como se definieron en la presente, dichos compuestos poseen propiedades para antagonizar PCSK9. También se describen las formulaciones farmacéuticas que comprenden los compuestos de fórmula (1) o sus sales, y métodos de tratamiento de enfermedades cardiovasculares y de afecciones relacionadas con la actividad de PCSK9, por ejemplo, aterosclerosis, hipercolesterolemia, enfermedad coronaria, síndrome metabólico, síndrome coronario agudo, o enfermedad cardiovascular relacionada y afecciones cardiometabólicas.Compounds of formula (1), or a pharmaceutically acceptable salt thereof, where A, X, R¹, and R² are as defined herein, are disclosed, said compounds possess properties to antagonize PCSK9. Pharmaceutical formulations comprising the compounds of formula (1) or their salts, and methods of treating cardiovascular diseases and conditions related to PCSK9 activity, for example, atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, syndrome acute coronary, or related cardiovascular disease and cardiometabolic conditions.

ARP200102432A 2019-08-30 2020-08-28 PCSK9 ANTAGONIST COMPOUNDS AR119864A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962894286P 2019-08-30 2019-08-30

Publications (1)

Publication Number Publication Date
AR119864A1 true AR119864A1 (en) 2022-01-19

Family

ID=80633261

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102432A AR119864A1 (en) 2019-08-30 2020-08-28 PCSK9 ANTAGONIST COMPOUNDS

Country Status (1)

Country Link
AR (1) AR119864A1 (en)

Similar Documents

Publication Publication Date Title
AR115597A1 (en) PCSK9 ANTAGONIST COMPOUNDS
ECSP20001149A (en) ANTIPROLIFERATIVE COMPOUNDS AND METHODS TO USE THEM
AR103222A1 (en) PROCEDURE FOR THE PREPARATION OF ANALOGS OF 4-PHENYL-5-ALCOXICARBONIL-2-THIAZOL-2-IL-1,4-DIHYDROPIRIMIDINE
MX2021013472A (en) Modulators of thr-î² and methods of use thereof.
CY1118102T1 (en) DIAMINIUM SALT FANOTHEIAZINE AND THEIR USE
EA201800064A1 (en) 1,1,1-TRIFTOR-3-HYDROXYPROPAN-2-IL CARBAMATE DERIVATIVES AND 1,1,1-TRIFTOR-4-HYDROXYBUTAN-2-IL CARBAMATE DERIVATIVES AS MIGL INHIBITORS
BR112018070956A2 (en) compounds of the formula, pharmaceutical compositions and methods for delivering a nucleic acid to an animal's liver and for preparing a compound of the formula
CY1124210T1 (en) TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USING THEREOF
JP2014511892A5 (en)
UY33501A (en) Acyl sulfonamide derivatives and their pharmaceutically acceptable salts for use in medicine
AR065876A1 (en) ACTIVE COMPOUNDS FOR 11 BETA -HSD1
CL2020001090A1 (en) Pyrimidine compound as a janokinase inhibitor.
CL2021000514A1 (en) Dimethylaminoazetidinamines as jak inhibitors
CO6531452A2 (en) SUBSTITUTED PIPERIDINS THAT INCREASE THE ACTIVITY OF P53 AND ITS USES
AR112333A1 (en) PYRROLOPYRIMIDINE AND PYRROLOPYRIMIDINE DERIVATIVES
AR072085A1 (en) TRICICLIC COMPOUNDS, METHODS FOR THEIR PREPARATION, FARMA-CEUTICA COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEASURED BY THE ACTIVITY OF KINASE PROTEINS
CO2021005532A2 (en) Quinoline derivatives as inhibitors of integrin alpha4beta7
CR20150419A (en) SUBSTITUTED DERIVATIVES OF PHOSPHONE BISPHENILE ACID AS INHIBITORS OF THE NEP
BR112016013618A8 (en) maleimide derivatives as modulators of wnt reaction series, their uses, pharmaceutical composition and process for their preparation
BR112022008786A2 (en) COMPOUND, COMPOSITION, USE OF COMPOUND OR COMPOSITION, AND METHOD FOR TREATMENT OR PREVENTION OF A DIABETIC COMPLICATION, DISEASE RELATED TO NEUROINFLAMMATION OR ATHEROSCLEROSIS
CO2022008616A2 (en) Oral pharmaceutical composition comprising carbamate compound and method of preparation therefor
EA201590074A1 (en) BENZODIOXOL DERIVATIVE, METHOD FOR ITS PREPARATION AND ITS APPLICATION
AR119864A1 (en) PCSK9 ANTAGONIST COMPOUNDS
MA52587A (en) AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL
AR088845A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 7- (1H-IMIDAZOL-4-ILMETIL) -5,6,7,8-TETRAHYDRO-QUINOLINE FOR THE TREATMENT OF SKIN DISEASES AND AFFECTIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure